TECHNICAL COMMENTARY

NeuRA Discover. Conquer. Cure.

SCHIZOPHRENIA LIBRARY

Amphetamines

Introduction

Substance misuse is a significant problem for many people suffering from schizophrenia. It is unclear whether the use of illicit substances is a contributing factor to the development of schizophrenia, or alternatively whether schizophrenia is the cause of substance use, such that illicit substances may be used as a form of self-medication.

Method

We have included only systematic reviews (systematic literature search, detailed methodology with inclusion/exclusion criteria) published in full text, in English, from the year 2000 that report results separately for people with a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder or first episode schizophrenia. Reviews were identified by searching the databases MEDLINE, EMBASE, CINAHL, Current Contents, PsycINFO and the Cochrane library. Hand searching reference lists of identified reviews was also conducted. When multiple copies of reviews were found, only the most recent version was included. Reviews with pooled data are prioritised for inclusion.

Review reporting assessment was guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist that describes a preferred way to present a meta-analysis[1]. Reviews rated as having less than 50% of items checked have been excluded from the library. The PRISMA flow diagram is a suggested way of providing information about studies included and excluded with reasons for exclusion. Where no flow diagram has been presented by individual reviews, but identified studies have been described in the text, reviews have been checked for this item. Note that early reviews may have been guided by less stringent reporting checklists than the PRISMA, and that some reviews may have been limited by journal guidelines.

Evidence was graded using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group approach where high quality evidence such as that gained from randomised controlled trials (RCTs) may be downgraded to moderate or low if review and study quality is limited, if there is inconsistency in results, indirect comparisons, imprecise or sparse data and high probability of reporting bias. It may also be downgraded if risks associated with the intervention or other matter under review are high. Conversely, low quality evidence such as that gained from observational studies may be upgraded if effect sizes are large or if there is a dose dependent response. We have also taken into account sample size and whether results are consistent, precise and direct with low associated risks (see end of table for an explanation of these terms)[2]. The resulting table represents an objective summary of the available evidence, although the conclusions are solely the opinion of staff of NeuRA (Neuroscience Research Australia).

Results

We found three systematic reviews that met inclusion criteria[3-5].

- Moderate quality evidence suggests single dose dexamfetamine or methylphenidate may increase severity or frequency of positive symptoms, particularly in patients who are not in remission.
- Moderate to low quality evidence suggests no benefit of dexamfetamine or methylphenidate for symptoms or cognition when compared to placebo.

Margarete Ainsworth Building, Barker Street, Randwick NSW 2031. Phone: 02 9399 1000. Email: info@neura.edu.au

To donate, phone 1800 888 019 or visit www.neura.edu.au/donate/schizophrenia

NeuRA
Discover. Conquer. Cure.
SCHIZOPHRENIA LIBRARY

Curran C, Byrappa N, McBride A **Stimulant psychosis: Systematic review** **British Journal of Psychiatry 2004; 185: 196-204** View review abstract online	
Comparison	**Single dose oral or intravenous dexamfetamine or methylphenidate given to people with schizophrenia with psychotic symptoms vs. people with schizophrenia without psychotic symptoms (in remission) vs. controls.**
Summary of evidence	**Moderate to low quality evidence (small to medium-sized sample, unable to assess precision or consistency, direct) suggests single dose dexamfetamine or methylphenidate may increase positive symptom severity, particularly in patients who are not in remission.**
Psychotic symptoms	
Dexamfetamine was associated with a significant increase in the number of people with schizophrenia with pre-existing positive symptoms reporting a temporary increase in symptom severity when compared to people with schizophrenia who were in remission; 26 studies, N = 227 People with schizophrenia and psychotic symptoms = 51.4% People with schizophrenia who were in remission = 28.3% $\chi^2 = 46.3$, $p < 0.001$ Note: 10.2% of controls also reported brief positive symptoms	
Consistency in results‡	No measure of consistency is reported.
Precision in results§	No measure of precision is reported.
Directness of results‖	Direct

Nolte JP, Wong SD, Lachford G

Amphetamines for schizophrenia

NeuRA
Discover. Conquer. Cure.
SCHIZOPHRENIA LIBRARY

<table>
<tr><td colspan="2">Cochrane Database of Systematic Reviews 2004; 4: CD004964.
View review abstract online</td></tr>
<tr><td>Comparison</td><td>Amphetamines (a-amphetamine) vs. placebo (with or without ongoing antipsychotic medications).</td></tr>
<tr><td>Summary of evidence</td><td>Low quality evidence (very small samples, unable to assess consistency or precision, direct) is unable to determine the benefit of amphetamine for symptoms or physiology.</td></tr>
<tr><td colspan="2">Mental state (< 3 hours change in symptom severity)</td></tr>
<tr><td colspan="2">Patients receiving amphetamines showed significant improvements in negative symptom severity;
Positive symptoms (BPRS): 1 study, N = 16, WMD = 0.0, 95%CI -4.46 to 4.46, p = 1.0
Negative symptoms (ATS): 1 study, N = 16, WMD = -3.00, 95%CI -5.02 to -0.98, p = 0.0037</td></tr>
<tr><td colspan="2">Physiology</td></tr>
<tr><td colspan="2">Cerebral metabolism (<3.5 hours)
1 RCT (N = 23) reported significant increases in the cerebral metabolic rate (relative to the whole brain) following amphetamines administration, in the left cerebellum (WMD = 0.12, 95%CI 0.06 to 0.18, p < 0.001), right cerebellum (WMD = 0.12, 95%CI 0.06 to 0.18, p < 0.001), left striatum (WMD = 0.14, 95%CI 0.00 to 0.28, p = 0.045). Significant decreases in metabolism were reported in left dorsolateral prefrontal cortex (WMD = -0.09, 95%CI -0.17 to -0.01) and right dorsolateral prefrontal cortex (WMD = -0.04 95%CI -0.12 to 0.04).
There were no differences in cerebral metabolic rate of bilateral cerebellum, temporal lobes, orbitofrontal cortex, or thalami.
Cerebral blood flow (< 3 hours)
1 RCT (N = 24) reported significant reductions of blood flow in the left hemisphere (WMD = -13.6, 95%CI -18.56 to -8.64) and right hemisphere (WMD = -7.0, 95%CI -12.60 to -1.40) following amphetamines.
Cardiorespiratory function (< 1 hour)
1 RCT (N = 24) reported significant increase in systolic blood pressure (WMD = -3.10, 95%CI -10.45 to 4.25) following amphetamines, but there were no difference in pulse, respiration, diastolic pressure, or exhaled gases.
Cardiorespiratory function (by 4 weeks)
1 RCT (N = 20) reported no differences in pulse, systolic or diastolic pressure.</td></tr>
<tr><td>Risks</td><td>1 RCT reported neither group showed any changes in movement disorder severity (N = 16).</td></tr>
<tr><td>Consistency in results</td><td>No measure of consistency is reported.</td></tr>
</table>

Precision in results	No measure of precision is reported.
Directness of results	Direct

Solmi M, Fornaro M, Toyoshima K, Carvalho AF, Kohler CA, Veronese N, Stubbs B, De Bartolomeis A, Correll CU

Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder

CNS Spectrums 2018; 21: 1-17

View review abstract online

Comparison	**Dexamfetamine or methylphenidate vs. placebo.** **Some studies also included atomoxetine.**
Summary of evidence	**Moderate to low quality evidence (unclear samples, some inconsistency and imprecision, direct) suggests no benefit of dexamfetamine or methylphenidate for symptoms or cognition compared to placebo.**
Psychotic symptoms	
No significant differences between groups; 6 studies, N = unclear, SMD = 0.16, 95%CI -0.28 to 0.61, $p = 0.47$, $I^2 = 50\%$	
Negative symptoms	
No significant differences between groups; 7 studies, N = unclear, SMD = 0.02, 95%CI -0.25 to 0.30, $p = 0.86$, $I^2 = 0\%$	
Cognition	
No significant differences between groups; 2 studies, N = unclear, SMD = 0.80, 95%CI -1.68 to 0.08, $p = 0.08$, $I^2 = 66\%$	
Consistency in results	Some inconsistency

Amphetamines

Precision in results	Some imprecision
Directness of results	Direct

Explanation of acronyms

ATS = Abrams and Taylor Scale of Emotional Blunting, BPRS = Brief Psychiatric Rating Scale, CI = confidence interval, I^2 = the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance), N = number of participants, *p* = statistical probability of obtaining that result ($p < 0.05$ generally regarded as significant), RCT = randomised controlled trial, vs = versus, WMD = weighted mean difference

Margarete Ainsworth Building, Barker Street, Randwick NSW 2031. Phone: 02 9399 1000. Email: info@neura.edu.au

To donate, phone 1800 888 019 or visit www.neura.edu.au/donate/schizophrenia

Explanation of technical terms

* Bias has the potential to affect reviews of both RCT and observational studies. Forms of bias include; reporting bias – selective reporting of results; publication bias - trials that are not formally published tend to show less effect than published trials, further if there are statistically significant differences between groups in a trial, these trial results tend to get published before those of trials without significant differences; language bias – only including English language reports; funding bias - source of funding for the primary research with selective reporting of results within primary studies; outcome variable selection bias; database bias - including reports from some databases and not others; citation bias - preferential citation of authors. Trials can also be subject to bias when evaluators are not blind to treatment condition and selection bias of participants if trial samples are small[6].

† Different effect measures are reported by different reviews.

Prevalence refers to how many existing cases there are at a particular point in time. Incidence refers to how many new cases there are per population in a specified time period. Incidence is usually reported as the number of new cases per 100,000 people per year. Alternatively some studies present the number of new cases that have accumulated over several years against a person-years denominator. This denominator is the sum of individual units of time that the persons in the population are at risk of becoming a case. It takes into account the size of the underlying population sample and its age structure over the duration of observation.

Reliability and validity refers to how accurate the instrument is. Sensitivity is the proportion of actual positives that are correctly identified (100% sensitivity = correct identification of all actual positives) and specificity is the proportion of negatives that are correctly identified (100% specificity = not identifying anyone as positive if they are truly not).

Weighted mean difference scores refer to mean differences between treatment and comparison groups after treatment (or occasionally pre to post treatment) and in a randomised trial there is an assumption that both groups are comparable on this measure prior to treatment. Standardised mean differences are divided by the pooled standard deviation (or the standard deviation of one group when groups are homogenous), which allows results from different scales to be combined and compared. Each study's mean difference is then given a weighting depending on the size of the sample and the variability in the data. Less than 0.4 represents a small effect, around 0.5 a medium effect, and over 0.8 represents a large effect[6].

Odds ratio (OR) or relative risk (RR) refers to the probability of a reduction (< 1) or an increase (> 1) in a particular outcome in a treatment group, or a group exposed to a risk factor, relative to the comparison group. For example, a RR of 0.75 translates to a reduction in risk of an outcome of 25% relative to those not receiving the treatment or not exposed to the risk factor. Conversely, a RR of 1.25 translates to an increased risk of 25% relative to those not receiving treatment or not having been exposed to a risk factor. A RR or OR of 1.00 means there is no difference between groups. A medium effect is considered if RR > 2 or < 0.5 and a large effect if RR > 5 or < 0.2[7]. lnOR stands for logarithmic OR where a lnOR of 0 shows no difference between groups. Hazard ratios

Margarete Ainsworth Building, Barker Street, Randwick NSW 2031. Phone: 02 9399 1000. Email: info@neura.edu.au

To donate, phone 1800 888 019 or visit www.neura.edu.au/donate/schizophrenia

measure the effect of an explanatory variable on the hazard or risk of an event.

Correlation coefficients (eg, r) indicate the strength of association or relationship between variables. They can provide an indirect indication of prediction, but do not confirm causality due to possible and often unforseen confounding variables. An r of 0.10 represents a weak association, 0.25 a medium association and 0.40 and over represents a strong association. Unstandardised (*b*) regression coefficients indicate the average change in the dependent variable associated with a 1 unit change in the independent variable, statistically controlling for the other independent variables. Standardised regression coefficients represent the change being in units of standard deviations to allow comparison across different scales.

‡ Inconsistency refers to differing estimates of effect across studies (i.e. heterogeneity or variability in results) that is not explained by subgroup analyses and therefore reduces confidence in the effect estimate. I^2 is the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance) - 0% to 40%: heterogeneity might not be important, 30% to 60%: may represent moderate heterogeneity, 50% to 90%: may represent considerable heterogeneity and over this is considerable heterogeneity. I^2 can be calculated from Q (chi-square) for the test of heterogeneity with the following formula[6];

$$I^2 = \left(\frac{Q - df}{Q}\right) \times 100\%$$

§ Imprecision refers to wide confidence intervals indicating a lack of confidence in the effect estimate. Based on GRADE recommendations, a result for continuous data (standardised mean differences, not weighted mean differences) is considered imprecise if the upper or lower confidence limit crosses an effect size of 0.5 in either direction, and for binary and correlation data, an effect size of 0.25. GRADE also recommends downgrading the evidence when sample size is smaller than 300 (for binary data) and 400 (for continuous data), although for some topics, these criteria should be relaxed[8].

" Indirectness of comparison occurs when a comparison of intervention A versus B is not available but A was compared with C and B was compared with C that allows indirect comparisons of the magnitude of effect of A versus B. Indirectness of population, comparator and/or outcome can also occur when the available evidence regarding a particular population, intervention, comparator, or outcome is not available and is therefore inferred from available evidence. These inferred treatment effect sizes are of lower quality than those gained from head-to-head comparisons of A and B.

Margarete Ainsworth Building, Barker Street, Randwick NSW 2031. Phone: 02 9399 1000. Email: info@neura.edu.au

To donate, phone 1800 888 019 or visit www.neura.edu.au/donate/schizophrenia

NeuRA Discover. Conquer. Cure.

SCHIZOPHRENIA LIBRARY

References

1. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMAGroup (2009): Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *British Medical Journal* 151: 264-9.
2. GRADEWorkingGroup (2004): Grading quality of evidence and strength of recommendations. *British Medical Journal* 328: 1490.
3. Nolte S, Wong D, Lachford G (2004): Amphetamines for schizophrenia. *Cochrane Database of Systematic Reviews*: CD004964.
4. Curran C, Byrappa N, McBride A (2004): Stimulant psychosis: systematic review. *British Journal of Psychiatry* 185: 196-204.
5. Solmi M, Fornaro M, Toyoshima K, Carvalho AF, Kohler CA, Veronese N*, et al.* (2018): Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder. *CNS Spectrums* 21: 1-17.
6. CochraneCollaboration (2008): Cochrane Handbook for Systematic Reviews of Interventions. Accessed 24/06/2011.
7. Rosenthal JA (1996): Qualitative Descriptors of Strength of Association and Effect Size. *Journal of Social Service Research* 21: 37-59.
8. GRADEpro (2008): [Computer program]. Jan Brozek, Andrew Oxman, Holger Schünemann. *Version 32 for Windows*

Margarete Ainsworth Building, Barker Street, Randwick NSW 2031. Phone: 02 9399 1000. Email: info@neura.edu.au
To donate, phone 1800 888 019 or visit www.neura.edu.au/donate/schizophrenia